Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related THOR
Thoratec Receives Approval From FDA For Full Expansion Of HeartMate III™ U.S. IDE Clinical Trial
Credit Suisse Reiterates Outperform, Raises Price Target On Thoratec On Updated LVAD Estimates
Related LOW
Technical Expert Watching Wendys, Home Depot
UBS Analyst Weighs In On Lowe's And Target's Earnings
UBS believes Lowe's is still a good buy (GuruFocus)

Analysts at Goldman Sachs downgraded Thoratec (NASDAQ: THOR) from “buy” to “neutral.” The target price for Thoratec has been lowered from $42 to $37. Thoratec's shares closed at $32.60 on Friday.

Analysts at Oppenheimer downgraded Lowe's Companies (NYSE: LOW) from “outperform” to “perform.” The target price for Lowe's is set to $46. Lowe's shares closed at $42.67 on Friday.

Analysts at Keefe Bruyette & Woods downgraded Bank of America (NYSE: BAC) from “outperform” to “perform.” Bank of America's shares closed at $13.43 on Friday.

Jefferies downgraded Bed Bath & Beyond (NASDAQ: BBBY) from “buy” to “hold.” The target price for Bed Bath & Beyond has been lowered from $76 to $71. Bed Bath & Beyond's shares closed at $69.11 on Friday.

Latest Ratings for THOR

DateFirmActionFromTo
May 2015BarclaysMaintainsEqual-weight
May 2015JP MorganMaintains
Apr 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for THOR
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BBBY + BAC)

Around the Web, We're Loving...